Glutamate release inhibition ineffective in levodopa-induced motor complications

Bara-Jimenez W., Dimitrova T. D., Sherzai A., Aksu M., Chase T. N.

MOVEMENT DISORDERS, vol.21, no.9, pp.1380-1383, 2006 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 9
  • Publication Date: 2006
  • Doi Number: 10.1002/mds.20976
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1380-1383
  • Acibadem Mehmet Ali Aydinlar University Affiliated: No


Reported benefits of various glutamatergic receptor antagonists in Parkinson's disease (PD) prompted an evaluation of the antidyskinetic effect of a putative glutamate release inhibitor in 15 moderately advanced patients. In a 3-week, double-blind, proof-of-concept study, riluzole (200 mg/day) failed to alter parkinsonian or levodopa-induced motor complication severity. Opposing effects of a generalized inhibition of glutamate-mediated synaptic transmission may limit the usefulness of this approach to treat PD. (c) 2006 Movement Disorder Society.